Geron Q1 2023 Earnings Report $2.89 -0.03 (-1.03%) As of 04:00 PM Eastern Earnings HistoryForecast Geron EPS ResultsActual EPS-$0.07Consensus EPS -$0.09Beat/MissBeat by +$0.02One Year Ago EPS-$0.09Geron Revenue ResultsActual Revenue$0.02 millionExpected Revenue$0.14 millionBeat/MissMissed by -$120.00 thousandYoY Revenue GrowthN/AGeron Announcement DetailsQuarterQ1 2023Date5/11/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseGERN Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Geron Earnings HeadlinesGeron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO SalesJanuary 16 at 1:53 PM | seekingalpha.comGeron (GERN) Receives a Buy from BarclaysJanuary 15 at 6:18 PM | markets.businessinsider.comThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…January 17, 2025 | Crypto 101 Media (Ad)Strong Growth and Strategic Financial Management Bolster Buy Rating for Geron’s Promising Rytelo DrugJanuary 15 at 6:07 AM | markets.businessinsider.comGeron’s Promising Market Growth: Strong Sales Performance and Optimistic Financial GuidanceJanuary 14 at 3:50 AM | markets.businessinsider.comNeedham & Company LLC Raises Geron (NASDAQ:GERN) Price Target to $7.00January 14 at 3:37 AM | americanbankingnews.comSee More Geron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Geron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geron and other key companies, straight to your email. Email Address About GeronGeron (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.View Geron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Ameriprise Financial (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
